Categorynews

North America Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type – ResearchAndMarkets.com

September 9, 2020 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “North America Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country: Trend Forecast and Growth Opportunity” report has been added to ResearchAndMarkets.com’s offering.

North America antibiotics market is expected to grow by 2.3% annually in the forecast period and reach $14.67 billion by 2030 driven by rising incidences of bacterial infection, growing awareness and need for new drugs and treatment amid the COVID-19 epidemic.

Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.

In-depth qualitative analyses include identification and investigation of the following aspects:

  • Market Structure
  • Growth Drivers
  • Restraints and Challenges
  • Emerging Product Trends & Market Opportunities
  • Porter’s Five Forces

The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country.

Based on Drug Class, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. (Read more…)

  • Cephalosporin
  • Penicillin
  • Macrolides
  • Fluoroquinolones
  • Quinolones
  • Monobactam
  • Aminoglycosides
  • Carbapenem
  • Other Drug Classes

Based on Action Mechanism, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

  • Cell Wall Synthesis Inhibitors
  • Mycolic Acid Inhibitors
  • RNA Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • Other Mechanisms

Based on Drug Origin, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

  • Natural Antibiotics
  • Semi-synthetic Antibiotics
  • Synthetic Antibiotics

Based on Activity Spectrum, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

  • Broad-spectrum Antibiotics
  • Narrow-spectrum Antibiotics

Based on Route of Administration, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

  • Oral Administration
  • Intravenous Administration
  • Other Administration Routes

Based on Drug Type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

  • Brand Antibiotics
  • Generic Antibiotics

Geographically, the following national/local markets are fully investigated:

  • U.S.
  • Canada
  • Mexico

For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Drug Class, Drug Origin, and Route of Administration over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Key Players

  • Abbott Laboratories
  • Astellas Pharma
  • AstraZeneca Plc
  • Bayer AG
  • Bristol Myers Squibb Company
  • Cipla Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc.
  • Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
  • Mayne Pharma Group Ltd.
  • MELINTA THERAPEUTICS, INC.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/j4lhkl

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900